标题
Immune Infiltrates in Breast Cancer: Recent Updates and Clinical Implications
作者
关键词
-
出版物
Cells
Volume 10, Issue 2, Pages 223
出版商
MDPI AG
发表日期
2021-01-25
DOI
10.3390/cells10020223
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Pembrolizumab plus chemotherapy as neoadjuvant treatment for high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study
- (2020) P. Schmid et al. ANNALS OF ONCOLOGY
- Pembrolizumab for Early Triple-Negative Breast Cancer
- (2020) Peter Schmid et al. NEW ENGLAND JOURNAL OF MEDICINE
- KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab + chemotherapy versus placebo + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer.
- (2020) Javier Cortes et al. JOURNAL OF CLINICAL ONCOLOGY
- Tumor-infiltrating lymphocytes (TILs) in ER+/HER2− breast cancer
- (2020) C. Criscitiello et al. BREAST CANCER RESEARCH AND TREATMENT
- 162MO Neoadjuvant chemotherapy and immunotherapy in Luminal B BC: Results of the phase II GIADA trial
- (2020) M.V. Dieci et al. ANNALS OF ONCOLOGY
- LBA13 Tumour infiltrating lymphocytes (TILs), PD-L1 expression and their dynamics in the NeoTRIPaPDL1 trial
- (2020) G. Bianchini et al. ANNALS OF ONCOLOGY
- PIK3CA Mutation in the ShortHER Randomized Adjuvant Trial for Patients with Early HER2+ Breast Cancer: Association with Prognosis and Integration with PAM50 Subtype
- (2020) Valentina Guarneri et al. CLINICAL CANCER RESEARCH
- Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial
- (2020) Elizabeth A Mittendorf et al. LANCET
- Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial
- (2020) Leisha A Emens et al. LANCET ONCOLOGY
- The role of tumor-associated macrophages in the development, metastasis and treatment of breast cancer
- (2020) Jing Lu et al. PATHOLOGY RESEARCH AND PRACTICE
- Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer
- (2019) M V Dieci et al. ANNALS OF ONCOLOGY
- Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers
- (2019) Sherene Loi et al. JOURNAL OF CLINICAL ONCOLOGY
- Interaction of host immunity with HER2-targeted treatment and tumor heterogeneity in HER2-positive breast cancer
- (2019) Gaia Griguolo et al. Journal for ImmunoTherapy of Cancer
- Residual Disease after Neoadjuvant Therapy — Developing Drugs for High-Risk Early Breast Cancer
- (2019) Tatiana M. Prowell et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b–2 trial
- (2019) Sherene Loi et al. LANCET ONCOLOGY
- Stromal Tumor-infiltrating Lymphocytes in NRG Oncology/NSABP B-31 Adjuvant Trial for Early-stage HER2-positive Breast Cancer
- (2019) Rim S Kim et al. JNCI-Journal of the National Cancer Institute
- Spatially distinct tumor immune microenvironments stratify triple-negative breast cancers
- (2019) Tina Gruosso et al. JOURNAL OF CLINICAL INVESTIGATION
- A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple negative breast cancer – clinical results and biomarker analysis of GeparNuevo study
- (2019) S Loibl et al. ANNALS OF ONCOLOGY
- Genomic correlates of response to adjuvant trastuzumab (H) and pertuzumab (P) in HER2+ breast cancer (BC): Biomarker analysis of the APHINITY trial.
- (2019) Ian E. Krop et al. JOURNAL OF CLINICAL ONCOLOGY
- Editorial
- (2019) S Loi ANNALS OF ONCOLOGY
- Residual disease and immune infiltration as a new surrogate endpoint for TNBC post neoadjuvant chemotherapy
- (2019) Stephen L. Luen et al. Oncotarget
- Programmed Cell Death Ligand 1 in Breast Cancer: Technical Aspects, Prognostic Implications, and Predictive Value
- (2019) Federica Miglietta et al. ONCOLOGIST
- Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019
- (2019) H J Burstein et al. ANNALS OF ONCOLOGY
- 305OOverall survival (OS) in KATE2, a phase II study of programmed death ligand 1 (PD-L1) inhibitor atezolizumab (atezo)+trastuzumab emtansine (T-DM1) vs placebo (pbo)+T-DM1 in previously treated HER2+ advanced breast cancer (BC)
- (2019) L A Emens et al. ANNALS OF ONCOLOGY
- Evaluation of the Predictive Role of Tumor Immune Infiltrate in Patients with HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2 Therapy without Chemotherapy
- (2019) Carmine De Angelis et al. CLINICAL CANCER RESEARCH
- The Immune Microenvironment in Breast Carcinoma: Predictive and Prognostic Role in the Neoadjuvant Setting
- (2019) Nahla M. Badr et al. PATHOBIOLOGY
- Prognostic value of tumor-infiltrating lymphocytes in patients with early-stage triple-negative breast cancers (TNBC) who did not receive adjuvant chemotherapy
- (2019) J H Park et al. ANNALS OF ONCOLOGY
- Tumor‐associated macrophages secrete CC‐chemokine ligand 2 and induce tamoxifen resistance by activating PI3K/Akt/mTOR in breast cancer
- (2019) Dongbo Li et al. CANCER SCIENCE
- Evaluation of Immune Reaction and PD-L1 Expression Using Multiplex Immunohistochemistry in HER2-Positive Breast Cancer: The Association With Response to Anti-HER2 Neoadjuvant Therapy
- (2018) Yanjun Hou et al. Clinical Breast Cancer
- Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy
- (2018) Carsten Denkert et al. LANCET ONCOLOGY
- Single-cell profiling of breast cancer T cells reveals a tissue-resident memory subset associated with improved prognosis
- (2018) Peter Savas et al. NATURE MEDICINE
- Scoring of tumor-infiltrating lymphocytes: From visual estimation to machine learning
- (2018) F. Klauschen et al. SEMINARS IN CANCER BIOLOGY
- Immunological differences between primary and metastatic breast cancer
- (2018) B Szekely et al. ANNALS OF ONCOLOGY
- 9 weeks vs 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study
- (2018) P Conte et al. ANNALS OF ONCOLOGY
- Tumor-associated macrophages in breast cancer: Innocent bystander or important player?
- (2018) Si-Qi Qiu et al. CANCER TREATMENT REVIEWS
- Dynamic evaluation of the immune infiltrate and immune function genes as predictive markers for neoadjuvant chemotherapy in hormone receptor positive, HER2 negative breast cancer
- (2018) Alexios Matikas et al. OncoImmunology
- Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study
- (2018) S Adams et al. ANNALS OF ONCOLOGY
- Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
- (2018) Peter Schmid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study
- (2017) Stephen J Luen et al. LANCET ONCOLOGY
- Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer
- (2017) Maria Vittoria Dieci et al. SEMINARS IN CANCER BIOLOGY
- Predictive and prognostic significance of CD8+ tumor-infiltrating lymphocytes in patients with luminal B/HER 2 negative breast cancer treated with neoadjuvant chemotherapy
- (2017) Khalid Al-Saleh et al. Oncology Letters
- The Differential Contribution of the Innate Immune System to a Good Pathological Response in the Breast and Axillary Lymph Nodes Induced by Neoadjuvant Chemotherapy in Women with Large and Locally Advanced Breast Cancers
- (2017) Viriya Kaewkangsadan et al. Journal of Immunology Research
- Interplay between Natural Killer Cells and Anti-HER2 Antibodies: Perspectives for Breast Cancer Immunotherapy
- (2017) Aura Muntasell et al. Frontiers in Immunology
- Association Between Genomic Metrics and Immune Infiltration in Triple-Negative Breast Cancer
- (2017) Thomas Karn et al. JAMA Oncology
- RNA Sequencing to Predict Response to Neoadjuvant Anti-HER2 Therapy
- (2017) Debora Fumagalli et al. JAMA Oncology
- Role of Cytotoxic Tumor-Infiltrating Lymphocytes in Predicting Outcomes in Metastatic HER2-Positive Breast Cancer
- (2017) Shuzhen Liu et al. JAMA Oncology
- Tumor infiltrating lymphocytes and tertiary lymphoid structures in paired primary tumors and metastases from breast cancer patients
- (2016) C. Solinas et al. ANNALS OF ONCOLOGY
- Integrated evaluation of PAM50 subtypes and immune modulation of pCR in HER2-positive breast cancer patients treated with chemotherapy and HER2-targeted agents in the CherLOB trial
- (2016) M. V. Dieci et al. ANNALS OF ONCOLOGY
- The genomic landscape of breast cancer and its interaction with host immunity
- (2016) Stephen Luen et al. BREAST
- Tumour-infiltrating CD8 to FOXP3 lymphocyte ratio in predicting treatment responses to neoadjuvant chemotherapy of aggressive breast cancer
- (2016) Y. Asano et al. BRITISH JOURNAL OF SURGERY
- The immune system and hormone-receptor positive breast cancer: Is it really a dead end?
- (2016) Maria Vittoria Dieci et al. CANCER TREATMENT REVIEWS
- Multiparametric Genomic Assays for Breast Cancer: Time for the Next Generation?
- (2016) A. M. Brufsky et al. CLINICAL CANCER RESEARCH
- Relevance of Tumor-Infiltrating Immune Cell Composition and Functionality for Disease Outcome in Breast Cancer
- (2016) Rico D. Bense et al. JNCI-Journal of the National Cancer Institute
- Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: results of the ring studies of the international immuno-oncology biomarker working group
- (2016) Carsten Denkert et al. MODERN PATHOLOGY
- Immune infiltrates in the breast cancer microenvironment: detection, characterization and clinical implication
- (2016) Samantha Burugu et al. Breast Cancer
- Patterns of Immune Infiltration in Breast Cancer and Their Clinical Implications: A Gene-Expression-Based Retrospective Study
- (2016) H. Raza Ali et al. PLOS MEDICINE
- Relevance of Tumor-Infiltrating Immune Cell Composition and Functionality for Disease Outcome in Breast Cancer
- (2016) Rico D. Bense et al. JNCI-Journal of the National Cancer Institute
- Association of Stromal Tumor-Infiltrating Lymphocytes With Recurrence-Free Survival in the N9831 Adjuvant Trial in Patients With Early-Stage HER2-Positive Breast Cancer
- (2016) Edith A. Perez et al. JAMA Oncology
- Variation in the Incidence and Magnitude of Tumor-Infiltrating Lymphocytes in Breast Cancer Subtypes
- (2016) Sasha E. Stanton et al. JAMA Oncology
- Prognostic and predictive value of tumor-infiltrating lymphocytes in two phase III randomized adjuvant breast cancer trials
- (2015) M. V. Dieci et al. ANNALS OF ONCOLOGY
- High numbers of macrophages, especially M2-like (CD163-positive), correlate with hyaluronan accumulation and poor outcome in breast cancer
- (2015) Satu Tiainen et al. HISTOPATHOLOGY
- Genomic Analysis Reveals That Immune Function Genes Are Strongly Linked to Clinical Outcome in the North Central Cancer Treatment Group N9831 Adjuvant Trastuzumab Trial
- (2015) Edith A. Perez et al. JOURNAL OF CLINICAL ONCOLOGY
- Natural killer (NK) cell profiles in blood and tumour in women with large and locally advanced breast cancer (LLABC) and their contribution to a pathological complete response (PCR) in the tumour following neoadjuvant chemotherapy (NAC): differential restoration of blood profiles by NAC and surgery
- (2015) Chandan Verma et al. Journal of Translational Medicine
- Prognostic Value of Tumor-Associated Macrophages According to Histologic Locations and Hormone Receptor Status in Breast Cancer
- (2015) Jae Moon Gwak et al. PLoS One
- Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study
- (2014) M. V. Dieci et al. ANNALS OF ONCOLOGY
- Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial
- (2014) S. Loi et al. ANNALS OF ONCOLOGY
- Association between CD8+ T-cell infiltration and breast cancer survival in 12 439 patients
- (2014) H. R. Ali et al. ANNALS OF ONCOLOGY
- The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014
- (2014) R. Salgado et al. ANNALS OF ONCOLOGY
- Prognostic B-cell Signatures Using mRNA-Seq in Patients with Subtype-Specific Breast and Ovarian Cancer
- (2014) M. D. Iglesia et al. CLINICAL CANCER RESEARCH
- Multiplexed Quantitative Analysis of CD3, CD8, and CD20 Predicts Response to Neoadjuvant Chemotherapy in Breast Cancer
- (2014) J. R. Brown et al. CLINICAL CANCER RESEARCH
- Research-Based PAM50 Subtype Predictor Identifies Higher Responses and Improved Survival Outcomes in HER2-Positive Breast Cancer in the NOAH Study
- (2014) A. Prat et al. CLINICAL CANCER RESEARCH
- Oncogene addiction and immunity
- (2014) Peter Savas et al. CURRENT OPINION IN ONCOLOGY
- Molecular Features and Survival Outcomes of the Intrinsic Subtypes Within HER2-Positive Breast Cancer
- (2014) Aleix Prat et al. JNCI-Journal of the National Cancer Institute
- The immune system and response to HER2-targeted treatment in breast cancer
- (2014) Giampaolo Bianchini et al. LANCET ONCOLOGY
- High infiltration of tumor-associated macrophages in triple-negative breast cancer is associated with a higher risk of distant metastasis
- (2014) Zhong-Yu Yuan et al. OncoTargets and Therapy
- Tumour-infiltrating CD8+ lymphocytes as an independent predictive factor for pathological complete response to primary systemic therapy in breast cancer
- (2013) A N Seo et al. BRITISH JOURNAL OF CANCER
- Tumor-Associated Lymphocytes Predict Response to Neoadjuvant Chemotherapy in Breast Cancer Patients
- (2013) Hee Jin Lee et al. Journal of Breast Cancer
- Prognostic and Predictive Value of Tumor-Infiltrating Lymphocytes in a Phase III Randomized Adjuvant Breast Cancer Trial in Node-Positive Breast Cancer Comparing the Addition of Docetaxel to Doxorubicin With Doxorubicin-Based Chemotherapy: BIG 02-98
- (2013) Sherene Loi et al. JOURNAL OF CLINICAL ONCOLOGY
- Molecular signatures mostly associated with NK cells are predictive of relapse free survival in breast cancer patients
- (2013) Maria Ascierto et al. Journal of Translational Medicine
- High-Infiltration of Tumor-Associated Macrophages Predicts Unfavorable Clinical Outcome for Node-Negative Breast Cancer
- (2013) Yue Zhang et al. PLoS One
- Intratumoral regulatory T cells as an independent predictive factor for pathological complete response to neoadjuvant paclitaxel followed by 5-FU/epirubicin/cyclophosphamide in breast cancer patients
- (2012) Naofumi Oda et al. BREAST CANCER RESEARCH AND TREATMENT
- The role of the tumour inflammatory cell infiltrate in predicting recurrence and survival in patients with primary operable breast cancer
- (2012) Zahra M.A. Mohammed et al. CANCER TREATMENT REVIEWS
- Tumor-Infiltrating CD8+ Lymphocytes Predict Clinical Outcome in Breast Cancer
- (2011) Sahar M.A. Mahmoud et al. JOURNAL OF CLINICAL ONCOLOGY
- Tumour-infiltrating macrophages and clinical outcome in breast cancer
- (2011) S M A Mahmoud et al. JOURNAL OF CLINICAL PATHOLOGY
- Tumor-Associated Lymphocytes As an Independent Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer
- (2009) Carsten Denkert et al. JOURNAL OF CLINICAL ONCOLOGY
- Tumor-Infiltrating Lymphocytes Predict Response to Neoadjuvant Chemotherapy in Patients with Breast Carcinoma
- (2008) Helena Hornychová et al. CANCER INVESTIGATION
- Pathologic Complete Response to Neoadjuvant Chemotherapy of Breast Carcinoma Is Associated with the Disappearance of Tumor-Infiltrating Foxp3+ Regulatory T Cells
- (2008) S. Ladoire et al. CLINICAL CANCER RESEARCH
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started